<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Visvanathan K</submitter><funding>NCI NIH HHS</funding><funding>The John Fetting Fund for Breast Cancer Prevention</funding><pagination>9533461</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11401740</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>2022</volume><pubmed_abstract>&lt;h4>Introduction&lt;/h4>Critical regulatory genes are functionally silenced by DNA hypermethylation in breast cancer and premalignant lesions. The objective of this study was to examine whether DNA methylation assessed in random fine needle aspirates (rFNA) can be used to inform breast cancer risk.&lt;h4>Methods&lt;/h4>In 20 women with invasive breast cancer scheduled for surgery at Johns Hopkins Hospital, cumulative methylation status was assessed in a comprehensive manner. rFNA was performed on tumors, adjacent normal tissues, and all remaining quadrants. Pathology review was conducted on blocks from all excised tissue. The cumulative methylation index (CMI) for 12 genes was assessed by a highly sensitive QM-MSP assay in 280 aspirates and tissue from 11 incidental premalignant lesions. Mann-Whitn</pubmed_abstract><journal>The breast journal</journal><pubmed_title>Evaluating DNA Methylation in Random Fine Needle Aspirates from the Breast to Inform Cancer Risk.</pubmed_title><pmcid>PMC11401740</pmcid><funding_grant_id>P30 CA006973</funding_grant_id><funding_grant_id>NCIT32CA009314</funding_grant_id><funding_grant_id>T32 CA009314</funding_grant_id><funding_grant_id>NCIP30CA006973</funding_grant_id><pubmed_authors>Fetting J</pubmed_authors><pubmed_authors>Fackler MJ</pubmed_authors><pubmed_authors>Cimino-Mathews A</pubmed_authors><pubmed_authors>Sukumar S</pubmed_authors><pubmed_authors>May B</pubmed_authors><pubmed_authors>Jacobs L</pubmed_authors><pubmed_authors>Orellana M</pubmed_authors><pubmed_authors>Camp M</pubmed_authors><pubmed_authors>Habibi M</pubmed_authors><pubmed_authors>Visvanathan K</pubmed_authors><pubmed_authors>White MJ</pubmed_authors><pubmed_authors>Stearns V</pubmed_authors><pubmed_authors>Karia PS</pubmed_authors><pubmed_authors>VandenBussche CJ</pubmed_authors><pubmed_authors>Lange J</pubmed_authors><pubmed_authors>Euhus D</pubmed_authors></additional><is_claimable>false</is_claimable><name>Evaluating DNA Methylation in Random Fine Needle Aspirates from the Breast to Inform Cancer Risk.</name><description>&lt;h4>Introduction&lt;/h4>Critical regulatory genes are functionally silenced by DNA hypermethylation in breast cancer and premalignant lesions. The objective of this study was to examine whether DNA methylation assessed in random fine needle aspirates (rFNA) can be used to inform breast cancer risk.&lt;h4>Methods&lt;/h4>In 20 women with invasive breast cancer scheduled for surgery at Johns Hopkins Hospital, cumulative methylation status was assessed in a comprehensive manner. rFNA was performed on tumors, adjacent normal tissues, and all remaining quadrants. Pathology review was conducted on blocks from all excised tissue. The cumulative methylation index (CMI) for 12 genes was assessed by a highly sensitive QM-MSP assay in 280 aspirates and tissue from 11 incidental premalignant lesions. Mann-Whitn</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022</publication><modification>2026-06-02T03:17:14.833Z</modification><creation>2026-06-02T03:11:33.914Z</creation></dates><accession>S-EPMC11401740</accession><cross_references><pubmed>39741654</pubmed><doi>10.1155/2022/9533461</doi></cross_references></HashMap>